AKT1 and breast cancer: TRIM47 knockdown inhibited the occurrence and development of breast cancer by suppressing the PI3K/Akt pathway, which was reversed by treatment with the PI3K/Akt activator insulin-like growth factor-1 (IGF-1) (Wang et al., 2020).